Homocistein
Homocistein je neproteinska aminokiselina. On je homolog aminokiseline cisteina, od koje se razlikuje po dodatnoj metilenskoj (-CH2-) grupi. On se biosintetiše iz metionina uklanjanjem terminalne Cε metil grupe. Homocistein se može reciklisati u metionin ili konvertovati u cistein uz pomoć B-vitamina.
Homocistein | |||
---|---|---|---|
IUPAC ime |
| ||
Identifikacija | |||
CAS registarski broj | 454-29-5 , 6027-13-0 (L-isomer) | ||
PubChem[1][2] | 778 | ||
ChemSpider[3] | 757 | ||
UNII | 0LVT1QZ0BA | ||
EC-broj | 207-222-9 | ||
KEGG[4] | |||
ChEBI | 17230 | ||
ChEMBL[5] | CHEMBL310604 | ||
Jmol-3D slike | Slika 1 | ||
| |||
| |||
Svojstva | |||
Molekulska formula | C4H9NO2S | ||
Molarna masa | 135,18 g/mol | ||
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala | |||
Infobox references |
Detekcija visokih nivoa homocisteina je povezana sa kardiovaskularnim bolesima, mada snižavanje nivoa homocisteina ne poboljšava ishod oboljenja.[6] Povišeni novoi homocisteina su vezani za više stanja bolesti. Korisnost pokušaja snižavanja nivoa homocisteina je bilo nepotvršena ili neubedljiva.[7][8][9][10]
Reference
uredi- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G (2009). Martí-Carvajal, Arturo J. ur. „Homocysteine lowering interventions for preventing cardiovascular events”. Cochrane Database Syst Rev (4): CD006612. DOI:10.1002/14651858.CD006612.pub2. PMID 19821378.
- ↑ Martí-Carvajal, AJ; Solà, I; Lathyris, D; Salanti, G. (2009-10-07). „Homocysteine lowering interventions for preventing cardiovascular events.”. Cochrane database of systematic reviews (Online) (4): CD006612. DOI:10.1002/14651858.CD006612.pub2. PMID 19821378.
- ↑ Jardine, MJ; Kang, A; Zoungas, S; Navaneethan, SD; Ninomiya, T; Nigwekar, SU; Gallagher, MP; Cass, A; Strippoli, G; Perkovic, V. (2012-06-13). „The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.”. BMJ (Clinical research ed.) 344: e3533. PMC 3374481. PMID 22695899.
- ↑ Vizzardi, E; Bonadei, I; Zanini, G; Frattini, S; Fiorina, C; Raddino, R; Dei Cas, L. (January 2009). „Homocysteine and heart failure: an overview.”. Recent patents on cardiovascular drug discovery 4 (1): 15–21. PMID 19149701.
- ↑ Ahmadieh, H; Arabi, A. (October 2011). „Vitamins and bone health: beyond calcium and vitamin D.”. Nutrition Reviews 69 (10): 584–98. DOI:10.1111/j.1753-4887.2011.00372.x. PMID 21967159.
Spoljašnje veze
uredi- David Spence on homocysteine levels, kidney damage, and cardiovascular disease, The Health Report, Radio National, 24 May 2010